Denali Therapeutics (DNLI) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 37.6% versus a gain of 28.6%. Over five years, TRVI leads with a +918.6% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $1.87 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | TRVI |
|---|---|---|
| Share price | $19.16 | $13.14 |
| Market cap | $3.06B | $1.87B |
| 1-day change | -0.62% | -0.30% |
| YTD return | +16.05% | +4.95% |
| 1-year return | +28.59% | +37.59% |
| 5-year return | -57.95% | +918.60% |
| EPS (TTM) | $-2.82 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $20.22 |
| 52-week low | $13.75 | $9.28 |
| Distance from 52-week high | -29.82% | -35.01% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.20% | +114.46% |
| Average volume | 1.61M | 1.91M |
| Shares outstanding | 159.85M | 142.48M |
| Employees | 503 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Healthcare · Biotechnology · 503 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Healthcare · Biotechnology · 34 employees
DNLI vs TRVI FAQ
Which is bigger, Denali Therapeutics or Trevi Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $1.87B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, DNLI or TRVI?
TRVI returned +37.59% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.